Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
about
ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virusThe B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promotersMethyl-dependent and spatial-specific DNA recognition by the orthologous transcription factors human AP-1 and Epstein-Barr virus ZtaEpstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinasesSumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation.BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186.Kaposi's sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification.Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomesUse of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replicationTegument protein control of latent herpesvirus establishment and animation.Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent mannerPhosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta.Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latencyPhosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes.Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoterThe cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuliProtein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA.The B-cell-specific transcription factor and master regulator Pax5 promotes Epstein-Barr virus latency by negatively regulating the viral immediate early protein BZLF1.Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1.The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells.Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.Essential role of Rta in lytic DNA replication of Epstein-Barr virusMultivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain.Amino acid substitutions reveal distinct functions of serine 186 of the ZEBRA protein in activation of early lytic cycle genes and synergy with the Epstein-Barr virus R transactivatorRole of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes.Disruption of Epstein-Barr virus latency in the absence of phosphorylation of ZEBRA by protein kinase C.Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) replication and transcription factor activates the K9 (vIRF) gene through two distinct cis elements by a non-DNA-binding mechanism.Two phenylalanines in the C-terminus of Epstein-Barr virus Rta protein reciprocally modulate its DNA binding and transactivation function.Stimulus duration and response time independently influence the kinetics of lytic cycle reactivation of Epstein-Barr virus.Mutations of amino acids in the DNA-recognition domain of Epstein-Barr virus ZEBRA protein alter its sub-nuclear localization and affect formation of replication compartments.A redox-sensitive cysteine in Zta is required for Epstein-Barr virus lytic cycle DNA replication.Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
P2860
Q28471803-8D668BC3-2EA5-431A-8663-D9BE2245FFFAQ28480586-F05D772D-5FB0-4ACB-8C73-35BCEE67CE32Q33422971-A10B5285-C214-41AA-A5DD-35DA3F987EACQ33557545-D94B9FC7-59D7-4243-AE6C-19FA4745A724Q33793163-2DDBB8B3-6DF2-4DCA-A570-D6799E839DC1Q33826641-53423290-F78C-4F31-91DE-FA55910A5D1CQ33842581-992A81EA-B4A7-4E5D-B591-BF9E1F1C0614Q33842700-DCC40E0D-EC4C-44C3-9F21-436C45801C93Q33843046-1B885A55-144B-4A7B-A14A-6661CB0FD94AQ33908645-28172395-A8F2-4C81-B658-DC0131754702Q34337317-4CA66B4B-B951-4DCF-9640-BE9F7ADAF36AQ34350013-38ADDA08-3019-4920-88BE-B4DA52685A0BQ34553293-7393C54F-B15C-40B3-A9FC-1413984A03C4Q34712750-9284D025-04D0-4601-A7E4-7B0353661816Q35024349-AC4C262A-027C-4533-8B73-98D843F57A70Q35076801-EE3A3260-5EA4-4F4F-8F2D-8EC24F94B6FDQ35122852-78CA4C06-B98A-4B42-B4D8-2212C19140F6Q35192797-700D5E46-3EDF-4536-AFC2-76FF0AD30F76Q35785209-7F31CED9-0A41-4153-92B0-587ED0E6B592Q35857370-CD4A44B0-DFBA-4E97-AA6E-697564B88155Q36414572-5DE09F50-5CDB-460C-8269-2A62CA757349Q36442795-342E627E-13A7-4736-BBDE-8D0393DADCBDQ36559479-25482C7F-61D2-4575-AB9B-D1D197AF3139Q36855331-7B8AE2C8-7D9A-485D-A925-4419F11CD7D8Q36978595-4EFF6A23-4096-427A-ACD9-7C8E172EE9C7Q37093515-3D81BE30-5F82-4EF5-80D8-E3F386411A7FQ37730699-AA3A6C3A-6E23-4D08-8017-1AD2BF8E1641Q38360833-DFD3D20B-440E-46B6-A7CF-F8A627B6572DQ38849926-A52CBE9E-58A1-4A4D-BBF1-ACA8D86F1511Q39257214-789E1962-C8E6-4EC4-AE12-8F49BDD4B0E7Q39305664-07460C1B-C74C-4D8C-B88E-7910A54C2524Q39593916-67A1AD1C-E3FF-4561-B1A8-6A59DECB6C0CQ39596888-E5E6AA9F-B5F9-4BD8-A563-58507A88A3E4Q39685869-7FC3C005-0347-473D-8C06-E2CE8CB1BC1DQ39686204-4242BCD0-1055-4BA1-A564-5C5C1A4687EFQ39779375-3F6EB281-421F-4CCE-B896-DA7851F3621EQ39816440-7B17AE17-4DE1-4D67-B595-8B4842241D33Q39927224-9B292D0E-A5F2-4F84-BE9A-1FE2684DDB06Q40361661-A629BDFF-1BAA-4FA9-836E-F5E88247D307Q40491223-9C248774-F8EF-408E-A4B9-EFA2356A39A3
P2860
Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@en
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@nl
type
label
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@en
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@nl
prefLabel
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@en
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@nl
P356
P1433
P1476
Rescue of the Epstein-Barr vir ...... ect by the BRLF1 gene product.
@en
P2093
P304
P356
10.1006/VIRO.1998.9396
P407
P577
1998-11-01T00:00:00Z